The development of MetAP-2 inhibitors in cancer treatment

Current Medicinal Chemistry

Volumn 19, Issue 7, 2012, Pages 1021-1035

  Yin, S Q ^a   Wang, J J ^a   Zhang, C M ^a   Liu, Z P ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis inhibitor; Antiangiogenesis; Cancer; Endothelial cells; Fumagillin; MetAP 2; MetAP 2 inhibitors; Metastasis; Methionine; Migration; Structure activity relationship; Vascular endothelial growth factor

Indexed keywords

2 HYDROXY 3 AMINOAMIDE DERIVATIVE; 5 NOROVALICIN; A 357300; ANGIOGENESIS INHIBITOR; ANTHRANILIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BENGAMIDE A; BENGAMIDE B; CAPECITABINE; CKD 731; CKD 732; FUMAGALONE; FUMAGILLIN; FUMAGILLIN DERIVATIVE; FUMAGILLOL CHLOROACETYLCARBAMATE; FUMARRANOL; IDR 803; IDR 804; IDR 805; METHIONYL AMINOPEPTIDASE 2; METHIONYL AMINOPEPTIDASE 2 INHIBITOR; OVALICIN; OXALIPLATIN; PEPTIDE HYDROLASE INHIBITOR; PPI 2458; RK 805; RK 95113; SULFONAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; ATAXIA; BREAST CARCINOMA; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; CONFUSION; DIZZINESS; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSPHORIA; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; INSOMNIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; MALAISE; METASTASIS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CARCINOMA; PROTEIN DEGRADATION; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CARCINOMA; VERTIGO;

EID: 84863248391     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799320709     Document Type: Review

References (78)

1. Giglione, C.; Serero, A.; Pierre, M.; Boisson, B.; Meinnel, T. Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J., 2000, 19, 5916-5929.
2. Sato, Y. Aminopeptidases and angiogenesis. Endothelium, 2003, 10, 287-290. (Pubitemid 38208071)
3. Lowther, W.T.; Matthews, B.W. Structure and function of the methionine aminopeptidases. Biochim. Biophys. Acta, 2000, 1477, 157-167. (Pubitemid 30119899)
4. Lowther, W.T.; Matthews, B.W. Metalloaminopeptidases: common functional themes in disparate structural surroundings. Chem. Rev., 2002, 102, 4581-4608.
5. Datta, B. Roles of P67/MetAP2 as a tumor suppressor. Biochim. Biophys. Acta, 2009, 1796, 281-292.
6. Wang, J.; Sheppard, G.S.; Lou, P.; Kawai, M.; Park, C.; Egan, D.A.; Schneider, A.; Bouska, J.; Lesniewski, R.; Henkin, J. Physiologically relevant metal cofactor for methionine aminopeptidase-2 is manganese. Biochemistry, 2003, 42, 5035-5042. (Pubitemid 36532057)
7. Yang, G.; Kirkpatrick, R.B.; Ho, T.; Zhang, G.F.; Liang, P.H.; Johanson, K.O.; Casper, D.J.; Doyle, M.L.; Marino, J.P., Jr.; Thompson, S.K.; Chen, W.; Tew, D.G.; Meek, T.D. Steady-state kinetic characterization of substrates and metal-ion specificities of the full-length and N-terminally truncated recombinant human methionine aminopeptidases (type 2). Biochemistry, 2001, 40, 10645-10654. (Pubitemid 32816677)
8. Ye, Q.Z.; Xie, S.X.; Ma, Z.Q.; Huang, M.; Hanzlik, R.P. Structural basis of catalysis by monometalated methionine aminopeptidase. Proc. Natl. Acad. Sci. USA, 2006, 103, 9470-9475. (Pubitemid 43955849)
9. Hu, X.; Addlagatta, A.; Lu, J.; Matthews, B.W.; Liu, J.O. Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression. Proc. Natl. Acad. Sci. USA, 2006, 103, 18148-18153. (Pubitemid 44871627)
10. Leszczyniecka, M.; Bhatia, U.; Cueto, M.; Nirmala, N.R.; Towbin, H.; Vattay, A.; Wang, B.; Zabludoff, S.; Phillips, P.E. MAP1D, a novel methionine aminopeptidase family member is overexpressed in colon cancer. Oncogene, 2006, 25, 3471-3478. (Pubitemid 43877050)
11. Tucker, L.A.; Zhang, Q.; Sheppard, G.S.; Lou, P.; Jiang, F.; McKeegan, E.; Lesniewski, R.; Davidsen, S.K.; Bell, R.L.; Wang, J. Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation. Oncogene, 2008, 27, 3967-3976. (Pubitemid 351913632)
12. Endo, H.; Takenaga, K.; Kanno, T.; Satoh, H.; Mori, S. Methionine aminopeptidase 2 is a new target for the metastasis-associated protein, S100A4. J. Biol. Chem., 2002, 277, 26396-26402. (Pubitemid 34967133)
13. Mauriz, J.L.; Martin-Renedo, J.; Garcia-Palomo, A.; Tunon, M.J.; Gonzalez- Gallego, J. Methionine aminopeptidases as potential targets for treatment of gastrointestinal cancers and other tumours. Curr. Drug Targets, 2010, 11, 1439-1457.
14. Bernier, S.G.; Westlin, W.F.; Hannig, G. Fumagillin class inhibitors of methionine aminopeptidase-2. Drugs Fut., 2005, 30, 497-508. (Pubitemid 40991871)
15. Bernier, S.G.; Lazarus, D.D.; Clark, E.; Doyle, B.; Labenski, M.T.; Thompson, C.D.; Westlin, W.F.; Hannig, G. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc. Natl. Acad. Sci. USA, 2004, 101, 10768-10773. (Pubitemid 38955817)
16. Lefkove, B.; Govindarajan, B.; Arbiser, J.L. Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors. Expert Rev. Anti-infect. Ther., 2007, 5, 573-579. (Pubitemid 47250132)
17. Ingber, D.; Fujita, T.; Kishimoto, S.; Sudo, K.; Kanamaru, T.; Brem, H.; Folkman, J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature, 1990, 348, 555-557. (Pubitemid 120015110)
18. Sin, N.; Meng, L.; Wang, M.Q.; Wen, J.J.; Bornmann, W.G.; Crews, C.M. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA, 1997, 94, 6099-6103. (Pubitemid 27270643)
19. Chen, G.J.; Weylie, B.; Hu, C.; Zhu, J.; Forough, R. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470). J. Cell. Biochem., 2007, 101, 1492-1504. (Pubitemid 47242778)
20. Molina, J.M.; Goguel, J.; Sarfati, C.; Michiels, J.F.; Desportes-Livage, I.; Balkan, S.; Chastang, C.; Cotte, L.; Maslo, C.; Struxiano, A.; Derouin, F.; Decazes, J.M. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. AIDS, 2000, 14, 1341-1348.
21. Sheen, I.S.; Jeng, K.S.; Jeng, W.J.; Jeng, C.J.; Wang, Y.C.; Gu, S.L.; Tseng, S.Y.; Chu, C.M.; Lin, C.H.; Chang, K.M. Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis. World J. Gastroenterol., 2005, 11, 771-777.
22. Hou, L.; Mori, D.; Takase, Y.; Meihua, P.; Kai, K.; Tokunaga, O. Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis. Pathol. Int., 2009, 59, 448-461.
23. Kusaka, M.; Sudo, K.; Fujita, T.; Marui, S.; Itoh, F.; Ingber, D.; Folkman, J. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun., 1991, 174, 1070-1076.
24. Yeh, J.R.; Mohan, R.; Crews, C.M. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc. Natl. Acad. Sci. USA, 2000, 97, 12782-12787.
25. Ogata, T.; Kurabayashi, M.; Maeno, T.; Sekiguchi, K.; Hoshino, Y.; Ishikawa, S.; Takei, H.; Nagai, R.; Morishita, Y. Angiogenesis inhibitor TNP-470 (AGM-1470) suppresses vascular smooth muscle cell proliferation after balloon injury in rats. J. Surg. Res., 2003, 112, 117-121. (Pubitemid 36904035)
26. Kruger, E.A.; Figg, W.D. TNP-470: an angiogenesis inhibitor in clinical development for cancer. Expert Opin. Investig. Drugs, 2000, 9, 1383-1396. (Pubitemid 30342622)
27. Herbst, R.S.; Madden, T.L.; Tran, H.T.; Blumenschein, G.R., Jr.; Meyers, C.A.; Seabrooke, L.F.; Khuri, F.R.; Puduvalli, V.K.; Allgood, V.; Fritsche, H.A., Jr.; Hinton, L.; Newman, R.A.; Crane, E.A.; Fossella, F.V.; Dordal, M.; Goodin, T.; Hong, W.K. Safety and pharmacokinetic effects of TNP- 470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol., 2002, 20, 4440-4447. (Pubitemid 35334755)
28. Logothetis, C.J.; Wu, K.K.; Finn, L.D.; Daliani, D.; Figg, W.; Ghaddar, H.; Gutterman, J.U. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res., 2001, 7, 1198-1203. (Pubitemid 32708670)
29. Satchi-Fainaro, R.; Puder, M.; Davies, J.W.; Tran, H.T.; Sampson, D.A.; Greene, A.K.; Corfas, G.; Folkman, J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med., 2004, 10, 255-261. (Pubitemid 38667615)
30. Segal, E.; Pan, H.; Benayoun, L.; Kopeckova, P.; Shaked, Y.; Kopecek, J.; Satchi-Fainaro, R. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials, 2011, 32, 4450-4463.
31. Asami, Y.; Kakeya, H.; Onose, R.; Chang, Y.H.; Toi, M.; Osada, H. RK-805, an endothelial-cell-growth inhibitor produced by Neosartorya sp., and a docking model with methionine aminopeptidase-2. Tetrahedron, 2004, 60, 7085-7091. (Pubitemid 38942935)
32. Lu, J.; Chong, C.R.; Hu, X.; Liu, J.O. Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo. J. Med. Chem., 2006, 49, 5645-5648. (Pubitemid 44423702)
33. Zhou, G.; Tsai, C.W.; Liu, J.O. Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis. J. Med. Chem., 2003, 46, 3452-3454. (Pubitemid 36909820)
34. Son, K.H.; Kwon, J.Y.; Jeong, H.W.; Kim, H.K.; Kim, C.J.; Chang, Y.H.; Choi, J.D.; Kwon, B.M. 5-demethylovalicin, as a methionine aminopeptidase-2 inhibitor produced by Chrysosporium. Bioorg. Med. Chem., 2002, 10, 185-188.
35. Asami, Y.; Kakeya, H.; Okada, G.; Toi, M.; Osada, H. RK-95113, a new angiogenesis inhibitor produced by Aspergillus fumigatus. J. Antibiot., 2006, 59, 724-728. (Pubitemid 46065468)
36. Han, C.K.; Ahn, S.K.; Choi, N.S.; Hong, R.K.; Moon, S.K.; Chun, H.S.; Lee, S.J.; Kim, J.W.; Hong, C.I.; Kim, D.; Yoon, J.H.; No, K.T. Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2. Bioorg. Med. Chem. Lett., 2000, 10, 39-43. (Pubitemid 30014666)
37. Chun, E.; Han, C.K.; Yoon, J.H.; Sim, T.B.; Kim, Y.K.; Lee, K.Y. Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model. Int. J. Cancer, 2005, 114, 124-130.
38. Kim, E.J.; Shin, W.H. General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system. Biol. Pharm. Bull., 2005, 28, 217-223.
39. Shin, S.J.; Jeung, H.C.; Ahn, J.B.; Rha, S.Y.; Roh, J.K.; Park, K.S.; Kim, D.H.; Kim, C.; Chung, H.C. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest. New Drugs, 2010, 28, 650-658.
40. Shin, S.J.; Ahn, J.B.; Park, K.S.; Lee, Y.J.; Hong, Y.S.; Kim, T.W.; Kim, H.R.; Rha, S.Y.; Roh, J.K.; Kim, D.H.; Kim, C.; Chung, H.C. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Invest. New Drugs: doi 10.1007/s10637-010-9625-x
41. Pyun, H.J.; Fardis, M.; Tario, J.; Yang, C.Y.; Ruckman, J.; Henninger, D.; Jin, H.L.; Kim, C.U. Investigation of novel fumagillin analogues as angiogenesis inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 91-94. (Pubitemid 38010200)
42. Bernier, S.G.; Taghizadeh, N.; Thompson, C.D.; Westlin, W.F.; Hannig, G. Methionine aminopeptidases type I and type II are essential to control cell proliferation. J. Cell. Biochem., 2005, 95, 1191-1203. (Pubitemid 41420126)
43. Hannig, G.; Lazarus, D.D.; Bernier, S.G.; Karp, R.M.; Lorusso, J.; Qiu, D.; Labenski, M.T.; Wakefield, J.D.; Thompson, C.D.; Westlin, W.F. Inhibitionof melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458. Int. J. Oncol., 2006, 28, 955-963.
44. Cooper, A.C.; Karp, R.M.; Clark, E.J.; Taghizadeh, N.R.; Hoyt, J.G.; Labenski, M.T.; Murray, M.J.; Hannig, G.; Westlin, W.F.; Thompson, C.D. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non- Hodgkin's lymphoma cell proliferation in vitro and in vivo. Clin. Cancer Res., 2006, 12, 2583-2590.
45. Arico-Muendel, C.C.; Benjamin, D.R.; Caiazzo, T.M.; Centrella, P.A.; Contonio, B.D.; Cook, C.M.; Doyle, E.G.; Hannig, G.; Labenski, M.T.; Searle, L.L.; Lind, K.; Morgan, B.A.; Olson, G.; Paradise, C.L.; Self, C.; Skinner, S.R.; Sluboski, B.; Svendsen, J.L.; Thompson, C.D.; Westlin, W.; White, K.F. Carbamate analogues of fumagillin as potent, targeted inhibitors of methionine aminopeptidase-2. J. Med. Chem., 2009, 52, 8047-8056.
46. Griffith, E.C.; Su, Z.; Niwayama, S.; Ramsay, C.A.; Chang, Y.H.; Liu, J.O. Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc. Natl. Acad. Sci. USA, 1998, 95, 15183-15188. (Pubitemid 29018673)
47. Liu, S.; Widom, J.; Kemp, C.W.; Crews, C.M.; Clardy, J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science, 1998, 282, 1324-1327. (Pubitemid 28524496)
48. Rodeschini, V.; Boiteau, J.G.; Van de Weghe, P.; Tarnus, C.; Eustache, J. MetAP-2 inhibitors based on the fumagillin structure. Side-chain modification and ring-substituted analogues. J. Org. Chem., 2004, 69, 357-373. (Pubitemid 38101717)
49. Jeong, B.S.; Choi, N.S.; Ahn, S.K.; Bae, H.; Kim, H.S.; Kim, D. Total synthesis and antiangiogenic activity of cyclopentane analogues of fumagillol. Bioorg. Med. Chem. Lett., 2005, 15, 3580-3583. (Pubitemid 40942060)
50. Lee, H.W.; Cho, C.S.; Kang, S.K.; Yoo, Y.S.; Shin, J.S.; Ahn, S.K. Design, synthesis, and antiangiogenic effects of a series of potent novel fumagillin analogues. Chem. Pharm. Bull., 2007, 55, 1024-1029. (Pubitemid 47028524)
51. Suda, H.; Aoyagi, T.; Takeuchi, T.; Umezawa, H. Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Arch. Biochem. Biophys., 1976, 177, 196-200.
52. Burley, S.K.; David, P.R.; Lipscomb, W.N. Leucine aminopeptidase: bestatin inhibition and a model for enzyme-catalyzed peptide hydrolysis. Proc. Natl. Acad. Sci. USA, 1991, 88, 6916-6920. (Pubitemid 21915060)
53. Sheppard, G.S.; Wang, J.; Kawai, M.; BaMaung, N.Y.; Craig, R.A.; Erickson, S.A.; Lynch, L.; Patel, J.; Yang, F.; Searle, X.B.; Lou, P.; Park, C.; Kim, K.H.; Henkin, J.; Lesniewski, R. 3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2. Bioorg. Med. Chem. Lett., 2004, 14, 865-868.
54. Wang, J.; Sheppard, G.S.; Lou, P.; Kawai, M.; BaMaung, N.; Erickson, S.A.; Tucker-Garcia, L.; Park, C.; Bouska, J.; Wang, Y.C.; Frost, D.; Tapang, P.; Albert, D.H.; Morgan, S.J.; Morowitz, M.; Shusterman, S.; Maris, J.M.; Lesniewski, R.; Henkin, J. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res., 2003, 63, 7861-7869.
55. Morowitz, M.J.; Barr, R.; Wang, Q.; King, R.; Rhodin, N.; Pawel, B.; Zhao, H.; Erickson, S.A.; Sheppard, G.S.; Wang, J.; Maris, J.M.; Shusterman, S. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin. Cancer Res., 2005, 11, 2680-2685. (Pubitemid 40569469)
56. Shusterman, S.; Maris, J.M. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett., 2005, 228, 171-179. (Pubitemid 41188439)
57. Wang, J.; Tucker, L.A.; Stavropoulos, J.; Zhang, Q.; Wang, Y.C.; Bukofzer, G.; Niquette, A.; Meulbroek, J.A.; Barnes, D.M.; Shen, J.; Bouska, J.; Donawho, C.; Sheppard, G.S.; Bell, R.L. Correlation of tumor growth suppression and methionine aminopetidase-2 activity blockade using an orally active inhibitor. Proc. Natl. Acad. Sci. USA, 2008, 105, 1838-1843. (Pubitemid 351439426)
58. Jorgensen, A.T.; Sorensen, M.D.; Bjorkling, F.; Liljefors, T. Binding of α-hydroxy-β-amino acid inhibitors to methionine aminopeptidase. The performance of two types of scoring functions. J. Comput. Aided Mol. Des., 2003, 17, 383-397. (Pubitemid 37407549)
59. Towbin, H.; Bair, K.W.; DeCaprio, J.A.; Eck, M.J.; Kim, S.; Kinder, F.R.; Morollo, A.; Mueller, D.R.; Schindler, P.; Song, H.K.; van Oostrum, J.; Versace, R.W.; Voshol, H.; Wood, J.; Zabludoff, S.; Phillips, P.E. Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors. J. Biol. Chem., 2003, 278, 52964-52971. (Pubitemid 38035898)
60. Hu, X.; Dang, Y.; Tenney, K.; Crews, P.; Tsai, C.W.; Sixt, K.M.; Cole, P.A.; Liu, J.O. Regulation of c-Src nonreceptor tyrosine kinase activity by bengamide A through inhibition of methionine aminopeptidases. Chem. Biol., 2007, 14, 764-774. (Pubitemid 47081418)
61. Thale, Z.; Kinder, F.R.; Bair, K.W.; Bontempo, J.; Czuchta, A.M.; Versace, R.W.; Phillips, P.E.; Sanders, M.L.; Wattanasin, S.; Crews, P. Bengamides revisited: new structures and antitumor studies. J. Org. Chem., 2001, 66, 1733-1741. (Pubitemid 32205111)
62. Kinder, F.R., Jr.; Versace, R.W.; Bair, K.W.; Bontempo, J.M.; Cesarz, D.; Chen, S.; Crews, P.; Czuchta, A.M.; Jagoe, C.T.; Mou, Y.; Nemzek, R.; Phillips, P.E.; Tran, L.D.; Wang, R.M.; Weltchek, S.; Zabludoff, S. Synthesis and antitumor activity of ester-modified analogues of bengamide B. J. Med. Chem., 2001, 44, 3692-3699. (Pubitemid 33026677)
63. Dumez, H.; Gall, H.; Capdeville, R.; Dutreix, C.; van Oosterom, A.T.; Giaccone, G. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anticancer Drugs, 2007, 18, 219-225. (Pubitemid 44967432)
64. Kim, S.; LaMontagne, K.; Sabio, M.; Sharma, S.; Versace, R.W.; Yusuff, N.; Phillips, P.E. Depletion of methionine aminopeptidase 2 does not alter cell response to fumagillin or bengamides. Cancer Res., 2004, 64, 2984-2987. (Pubitemid 38581392)
65. Kawai, M.; BaMaung, N.Y.; Fidanze, S.D.; Erickson, S.A.; Tedrow, J.S.; Sanders, W.J.; Vasudevan, A.; Park, C.; Hutchins, C.; Comess, K.M.; Kalvin, D.; Wang, J.; Zhang, Q.; Lou, P.; Tucker-Garcia, L.; Bouska, J.; Bell, R.L.; Lesniewski, R.; Henkin, J.; Sheppard, G.S. Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg. Med. Chem. Lett., 2006, 16, 3574-3577.
66. Sheppard, G.S.; Wang, J.; Kawai, M.; Fidanze, S.D.; BaMaung, N.Y.; Erickson, S.A.; Barnes, D.M.; Tedrow, J.S.; Kolaczkowski, L.; Vasudevan, A.; Park, D.C.; Wang, G.T.; Sanders, W.J.; Mantei, R.A.; Palazzo, F.; Tucker-Garcia, L.; Lou, P.; Zhang, Q.; Park, C.H.; Kim, K.H.; Petros, A.; Olejniczak, E.; Nettesheim, D.; Hajduk, P.; Henkin, J.; Lesniewski, R.; Davidsen, S.K.; Bell, R.L. Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding. J. Med. Chem., 2006, 49, 3832-3849.
67. Wang, G.T.; Mantei, R.A.; Kawai, M.; Tedrow, J.S.; Barnes, D.M.; Wang, J.; Zhang, Q.; Lou, P.; Garcia, L.A.; Bouska, J.; Yates, M.; Park, C.; Judge, R.A.; Lesniewski, R.; Sheppard, G.S.; Bell, R.L. Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids. Bioorg. Med. Chem. Lett., 2007, 17, 2817-2822. (Pubitemid 46636248)
68. Marino, J.P., Jr.; Fisher, P.W.; Hofmann, G.A.; Kirkpatrick, R.B.; Janson, C.A.; Johnson, R.K.; Ma, C.; Mattern, M.; Meek, T.D.; Ryan, M.D.; Schulz, C.; Smith, W.W.; Tew, D.G.; Tomazek, T.A., Jr.; Veber, D.F.; Xiong, W.C.; Yamamoto, Y.; Yamashita, K.; Yang, G.; Thompson, S.K. Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore. J. Med. Chem., 2007, 50, 3777-3785. (Pubitemid 47292041)
69. Scudiero, D.A.; Shoemaker, R.H.; Paull, K.D.; Monks, A.; Tierney, S.; Nofziger, T.H.; Currens, M.J.; Seniff, D.; Boyd, M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res., 1988, 48, 4827-4833.
70. Kallander, L.S.; Lu, Q.; Chen, W.; Tomaszek, T.; Yang, G.; Tew, D.; Meek, T.D.; Hofmann, G.A.; Schulz-Pritchard, C.K.; Smith, W.W.; Janson, C.A.; Ryan, M.D.; Zhang, G.F.; Johanson, K.O.; Kirkpatrick, R.B.; Ho, T.F.; Fisher, P.W.; Mattern, M.R.; Johnson, R.K.; Hansbury, M.J.; Winkler, J.D.; Ward, K.W.; Veber, D.F.; Thompson, S.K. 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J. Med. Chem., 2005, 48, 5644-5647. (Pubitemid 41298336)
71. Oefner, C.; Douangamath, A.; D'Arcy, A.; Hafeli, S.; Mareque, D.; Mac Sweeney, A.; Padilla, J.; Pierau, S.; Schulz, H.; Thormann, M.; Wadman, S.; Dale, G.E. The 1.15Å crystal structure of the Staphylococcus aureus methionyl-aminopeptidase and complexes with triazole based inhibitors. J. Mol. Biol., 2003, 332, 13-21. (Pubitemid 36999727)
72. Garrabrant, T.; Tuman, R.W.; Ludovici, D.; Tominovich, R.; Simoneaux, R.L.; Galemmo, R.A., Jr.; Johnson, D.L. Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2) fail to inhibit endothelial cell proliferation or formation of microvessels from rat aortic rings in vitro. Angiogenesis, 2004, 7, 91-96.
73. Zhao, Y.; Zhou, Y.; O'Boyle, K.M.; Murphy, P.V. Hybrids of 1- deoxynojirimycin and aryl-1,2,3-triazoles and biological studies related to angiogenesis. Bioorg. Med. Chem., 2008, 16, 6333-6337. (Pubitemid 351783422)
74. Zhao, Y.; Zhou, Y.; O'Boyle, K.M.; Murphy, P.V. Biological study of the angiogenesis inhibitor N-(8-(3-ethynylphenoxy)octyl-1-deoxynojirimycin. Chem. Biol. Drug Des., 2010, 75, 570-577.
75. Pati, H.N.; Das, U.; Quail, J.W.; Kawase, M.; Sakagami, H.; Dimmock, J.R. Cytotoxic 3,5-bis(benzylidene)piperidin-4-ones and N-acyl analogs displaying selective toxicity for malignant cells. Eur. J. Med. Chem., 2008, 43, 1-7.
76. Selvakumar, P.; Lakshmikuttyamma, A.; Das, U.; Pati, H.N.; Dimmock, J.R.; Sharma, R.K. NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells. Mol. Cancer, 2009, 8, 65-71.
77. Hu, X.; Addlagatta, A.; Matthews, B.W.; Liu, J.O. Identification of pyridinylpyrimidines as inhibitors of human methionine aminopeptidases. Angew. Chem. Int. Ed. Engl., 2006, 45, 3772-3775. (Pubitemid 44098920)
78. Shim, J.S.; Matsui, Y.; Bhat, S.; Nacev, B.A.; Xu, J.; Bhang, H.E.; Dhara, S.; Han, K.C.; Chong, C.R.; Pomper, M.G.; So, A.; Liu, J.O. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J. Natl. Cancer Inst., 2010, 102, 1855-1873.